Healthy, Liver Diseases, Obesity
Conditions
Brief summary
This study is open to adults who have different levels of liver problems and adults who are healthy. People with or without overweight or obesity can take part. This study has 2 parts. The purpose of Part 1 is to find out whether having liver problems influences how BI 456906 is taken up in the body. The purpose of Part 2 is to find out whether having liver problems influences how people with overweight and obesity tolerate different doses of BI 456906. In Part 1, participants get a single injection of BI 456906 under their skin and stay at the study site for 2 nights afterwards. They are in the study for about a month. During this time, they visit the study site about 8 more times. The doctors compare the amount of BI 456906 in the blood of healthy people and people with liver problems. In Part 2, participants get 1 or 2 injections of BI 456906 once a week under their skin for 28 weeks. At the beginning, they get lower doses of BI 456906. Over time, they get higher doses until they reach a certain dose of BI 456906. This dose is then maintained until the end of the treatment. Participants in Part 2 are in the study for about 7 months. During this time, they visit the study site about 16 times and get about 15 phone calls from the site staff. The doctors record the number of people with health problems that could have been caused by treatment with BI 456906. They compare the results between participants with liver problems and those without liver problems. In both parts, doctors also regularly check participants' health and take note of any unwanted effects.
Interventions
DRUGBI 456906
BI 456906
Sponsors
Boehringer Ingelheim
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
-Part A: * Male or female subjects with age ≥18 years (or the minimum country specific age of consent if \>18 years) and 75 years, inclusive at the screening visit. * Body mass index (BMI) of 18.5-40.0 kg/m2 (inclusive). * Signed and dated written informed consent in accordance with International Council on Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial. * Women of childbearing potential must be willing and able to use two forms of effective contraception where at least one form is highly effective method of birth control per ICH M3 (R2) that results in a low failure rate (i.e. \<1% per year when used consistently and correctly). A list of contraception methods meeting these criteria is provided in the subject information. Please note that oral contraceptives are not allowed during the treatment period. A woman is considered of childbearing potential, i.e. fertile, following menarche and until becoming post-menopausal unless permanently sterile. Permanent sterilisation methods include hysterectomy, bilateral salpingectomy and bilateral oophorectomy. Tubal ligation is NOT a method of permanent sterilisation. A postmenopausal state is defined as no menses for 12 months without an alternative medical cause. Further inclusion criteria apply. -Part B: * Male or female subjects between the ages of ≥18 (or the minimum country specific age of consent if \>18 years) and 75 years, inclusive, at the screening visit. * Subjects with overweight or obesity, defined as BMI ≥27 kg/m2 at the screening visit. * A minimum absolute body weight of 70 kg for females and 80 kg for males at the screening visit. * Signed and dated written informed consent in accordance with ICH-GCP and local legislation prior to admission to the trial. Further inclusion criteria apply.
Exclusion criteria
-Part A: * Estimated Glomerular Filtration Rate (eGFR) \<60 mL/min/1.73 m2 (Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] formula). * Personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2, manifest hypo- or hyperthyroidism at screening. * Calcitonin ≥20 pg/mL (5.84 pmol/L) at the screening visit. * History of chronic or acute pancreatitis or elevation of serum lipase/amylase \>2×ULN, or fasting serum triglyceride levels of \>500 mg/dL (\>5.65 mmol/L) at screening. Further
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Part A: Area under the concentration-time curve of BI 456906 in plasma over the time interval from 0 extrapolated to infinity (AUC0-∞) | Up to 360 hours |
| Part A: Maximum measured concentration of BI 456906 in plasma (Cmax) | Up to 360 hours |
| Part B: Percentage of patients treated who experience treatment-emergent adverse event | Up to Day 218 |
Secondary
| Measure | Time frame |
|---|---|
| Part A: Percentage of patients treated who experience treatment-emergent adverse event | Up to Day 35 |
Countries
Germany, Hungary, New Zealand, Poland, Slovakia, United States
Outcome results
None listed